Last updated: July 6, 2026
Zanzalintinib (XL092) is an investigational next-generation oral multikinase inhibitor from Exelixis, designed as a successor to cabozantinib (Cabometyx / XL184). It targets VEGFR2, MET, and AXL / MER (the TAM-family kinases) — the same core profile as cabozantinib, but engineered with a shorter plasma half-life intended to improve tolerability and enable smoother combination with checkpoint immunotherapy. It is not FDA-approved as of July 2026.
Mechanism of action:Zanzalintinib blocks VEGFR2 (shutting down tumor angiogenesis), MET (a driver of proliferation and anti-angiogenic resistance), and AXL and MER (TAM-family receptor kinases that promote treatment resistance and tumor immune evasion). Blocking AXL/MER and MET is thought to make tumors more responsive to checkpoint immunotherapy, which is why the large majority of zanzalintinib trials pair it with a PD-1/PD-L1 or CTLA-4 immunotherapy (nivolumab, pembrolizumab, atezolizumab, durvalumab + tremelimumab, cemiplimab).
Development status:Investigational. Exelixis's registrational STELLAR Phase 3 program spans metastatic colorectal cancer, first-line non-clear-cell renal cell carcinoma, and head and neck squamous cell carcinoma — those pivotal trials have completed enrollment and are therefore not in the actively-recruiting list below. The recruiting portfolio is broad, mirroring the cabozantinib tumor landscape, and includes the high-profile belzutifan + zanzalintinib RCC doublet (LITESPARK-034).
Cabozantinib (Cabometyx) is one of the most widely used targeted therapies in oncology — it is a backbone in kidney cancer, liver cancer, and thyroid cancer, and it works by hitting several tyrosine kinases at once (VEGFR, MET, AXL). But its long half-life means side effects (high blood pressure, hand-foot reactions, diarrhea, fatigue) build up and can be slow to reverse, which makes it harder to combine smoothly with immunotherapy. Zanzalintinib is Exelixis's attempt to keep cabozantinib's efficacy while fixing its tolerability — same core targets, but a shorter half-life so the drug clears faster and side effects are more manageable and reversible.
The immunotherapy-combination thesis. Beyond blocking blood-vessel growth, zanzalintinib inhibits AXL and MER, kinases that tumors use to evade the immune system. The idea is that adding zanzalintinib to a checkpoint inhibitor makes "cold" tumors more visible to the immune system — which is why nearly every zanzalintinib trial is a combination with immunotherapy rather than the drug alone. This is the central bet of the entire program.
The belzutifan combination. One of the most closely watched zanzalintinib studies pairs it with belzutifan (a HIF-2α inhibitor) in kidney cancer — the registrational LITESPARK-034 Phase 3 (NCT07489495). This HIF-2α + next-generation TKI doublet is a leading storyline in advanced clear-cell renal cell carcinoma for 2026.
Zanzalintinib is a small-molecule inhibitor of multiple receptor tyrosine kinases: VEGFR2 (vascular endothelial growth factor receptor 2, the master switch for tumor angiogenesis), MET (the hepatocyte growth factor receptor, a driver of invasion and a well-documented mechanism of escape from pure anti-VEGF therapy), and the TAM family — AXL and MER (kinases upregulated in treatment resistance and implicated in suppressing anti-tumor immunity). This VEGFR/MET/AXL profile is shared with lenvatinib and cabozantinib; for the cross-cancer view of this class see the Multikinase Inhibitors mechanism hub. The distinctive design goal for zanzalintinib is pharmacokinetic: a shorter half-life than cabozantinib to improve the therapeutic window in immunotherapy combinations.
Curated subset of recruiting / not-yet-recruiting interventional zanzalintinib trials in the ClinTrialFinder corpus as of July 2026 (36 total), grouped by cancer type. The registrational STELLAR Phase 3 trials (colorectal, non-clear-cell RCC, head & neck) have completed enrollment and are not listed here.
Zanzalintinib is best understood as Exelixis's next-generation cabozantinib: same VEGFR2/MET/AXL target profile, engineered for a shorter half-life and better combinability with immunotherapy. Cabozantinib is FDA-approved and widely used (RCC, HCC, thyroid, and more); zanzalintinib is investigational and aims to extend that franchise into new combinations and tumor types. The two share the same multikinase-inhibitor class as lenvatinib. The registrational STELLAR Phase 3 readouts (colorectal, non-clear-cell RCC, head & neck) will determine whether zanzalintinib earns its first approvals.
As a VEGFR/MET multikinase inhibitor, zanzalintinib's expected side effects follow the class shared with cabozantinib and lenvatinib: hypertension (high blood pressure), palmar-plantar erythrodysesthesia (hand-foot skin reaction), diarrhea, fatigue, decreased appetite, and transaminase (liver enzyme) elevation. The shorter half-life is intended to make these more manageable and reversible than with cabozantinib, particularly in combination with immunotherapy. As an investigational agent, zanzalintinib's full safety profile is still being characterized in the trials above.
What is zanzalintinib (XL092) and how does it work?
Zanzalintinib (XL092) is an investigational next-generation oral multikinase inhibitor from Exelixis. It blocks VEGFR2 (tumor blood-vessel growth), MET, and AXL/MER (TAM-family kinases involved in resistance and immune evasion). It was designed as a shorter-half-life successor to cabozantinib for better tolerability and immunotherapy combination. Not FDA-approved as of July 2026.
How is zanzalintinib different from cabozantinib?
Both are Exelixis oral multikinase inhibitors with the same core VEGFR2/MET/AXL profile. Zanzalintinib (XL092) has a shorter plasma half-life than cabozantinib (Cabometyx/XL184), intended to make side effects more manageable and reversible and to combine more smoothly with immunotherapy. Zanzalintinib is investigational; cabozantinib is FDA-approved.
What cancers is zanzalintinib being studied in?
Broadly, mirroring cabozantinib. The registrational STELLAR Phase 3 program covers metastatic colorectal cancer, first-line non-clear-cell RCC, and head & neck cancer. Recruiting Phase 2 trials span RCC (including the belzutifan + zanzalintinib LITESPARK-034 doublet), neuroendocrine tumors, hepatocellular carcinoma, thyroid cancer, castration-resistant prostate cancer, sarcoma, urothelial carcinoma, and meningioma — usually with PD-1/PD-L1 or CTLA-4 immunotherapy. See the full list above.
What is LITESPARK-034?
LITESPARK-034 (NCT07489495) is a recruiting Phase 3 trial combining belzutifan (a HIF-2α inhibitor) with zanzalintinib in renal cell carcinoma — the registrational test of the HIF-2α + next-gen TKI doublet in advanced clear-cell RCC.
What are the expected side effects of zanzalintinib?
As a VEGFR/MET multikinase inhibitor: hypertension, hand-foot skin reaction (palmar-plantar erythrodysesthesia), diarrhea, fatigue, decreased appetite, and liver enzyme (transaminase) elevation. The shorter half-life is intended to make these more manageable, especially in immunotherapy combinations. As an investigational drug, the full profile is still being characterized.
Find zanzalintinib / multikinase-inhibitor trials matched to your situation
Find Matching Trials